SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: QuietWon who wrote (1074)11/2/1999 9:20:00 PM
From: Pseudo Biologist  Read Replies (1) | Respond to of 2515
 
What the heck is right, here is a piece of the release:

<<the filing of an Investigational New Drug (IND) application for a vaccine against N. gonorrhea by Wyeth Lederle Vaccines – the vaccine unit of Wyeth-Ayerst Laboratories (the pharmaceutical division of AHP).>>

I had to read it a few times to make sure it is Wyeth (AHP) doing the filing, not Imclone. The latter apparently did some research on this long ago that enabled the development of this product.

Nice side show. Now, let's get this darned secondary out of the way.

PB



To: QuietWon who wrote (1074)11/2/1999 11:04:00 PM
From: synchro  Read Replies (1) | Respond to of 2515
 
After the recent detonations in several biotech stocks (GENZ and BGEN, which I still own, GILD, which I sold last Friday before the wringer on Monday), I can use any good biotech good news.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News